The emergent phenomenon of aspirin resistance: insights from genetic association studies

Pharmacogenomics. 2020 Jan;21(2):125-140. doi: 10.2217/pgs-2019-0133.

Abstract

Despite the clinical benefits of aspirin, the interindividual variation in response to this antiplatelet drug is considerable. The manifestation of aspirin resistance (AR) is frequently observed, although this complex process remains poorly understood. While AR etiology is likely to be multifactorial, genetic factors appear to be preponderant. According to several genetic association studies, both genome-wide and candidate gene studies, numerous SNPs in cyclooxygenase, thromboxane and platelet receptors-related genes have been identified as capable of negatively affecting aspirin action. Thus, it is essential to understand the clinical relevance of AR-related SNPs as potential predictive and prognostic biomarkers as they may be essential to defining the AR phenotype.

Keywords: GWAS; SNPs; aspirin; aspirin resistance; candidate gene studies; genetic association studies; genetic polymorphisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Drug Resistance / genetics*
  • Genetic Association Studies*
  • Genotype
  • Humans
  • Phenotype
  • Platelet Aggregation / drug effects
  • Platelet Aggregation / genetics
  • Platelet Aggregation Inhibitors / therapeutic use
  • Polymorphism, Single Nucleotide / genetics
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Thromboxanes / genetics

Substances

  • Platelet Aggregation Inhibitors
  • Thromboxanes
  • Prostaglandin-Endoperoxide Synthases
  • Aspirin